We are live on ! Find out more
NKTR icon

Nektar Therapeutics

199 hedge funds and large institutions have $1.78B invested in Nektar Therapeutics in 2016 Q4 according to their latest regulatory filings, with 37 funds opening new positions, 101 increasing their positions, 34 reducing their positions, and 28 closing their positions.

New
Increased
Maintained
Reduced
Closed

197% more repeat investments, than reductions

Existing positions increased: 101 | Existing positions reduced: 34

32% more first-time investments, than exits

New positions opened: 37 | Existing positions closed: 28

25% more call options, than puts

Call options by funds: $8.72M | Put options by funds: $7M

6.33% more ownership

Funds ownership: 0%6.33% (+6.3%)

3% more funds holding

Funds holding: 194199 (+5)

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

22% less capital invested

Capital invested by funds: $2.28B → $1.78B (-$503M)

Holders
199
Holders Change
+5
Holders Change %
+2.58%
% of All Funds
4.97%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.02%
New
37
Increased
101
Reduced
34
Closed
28
Calls
$8.72M
Puts
$7M
Net Calls
+$1.73M
Net Calls Change
+$3.03M
Name Holding Trade Value Shares
Change
Change in
Stake
Prudential Financial
51
Prudential Financial
New Jersey
$3.18M +$247K +1,216 +8%
New York State Teachers Retirement System (NYSTRS)
52
New York State Teachers Retirement System (NYSTRS)
New York
$3.13M +$17.7K +87 +0.5%
SEI Investments
53
SEI Investments
Pennsylvania
$3.11M +$3.34M +16,447 +3,463%
Swiss National Bank
54
Swiss National Bank
Switzerland
$3.02M +$356K +1,753 +12%
PP
55
PDT Partners
New York
$3.02M +$575K +2,826 +21%
PPA
56
Parametric Portfolio Associates
Washington
$2.83M +$1.02M +5,024 +49%
AllianceBernstein
57
AllianceBernstein
Tennessee
$2.73M -$248K -1,220 -8%
RhumbLine Advisers
58
RhumbLine Advisers
Massachusetts
$2.71M +$315K +1,548 +12%
JGC
59
J. Goldman & Co
New York
$2.54M +$2.8M +13,773 New
New York State Common Retirement Fund
60
New York State Common Retirement Fund
New York
$2.48M +$164K +806 +6%
TAM
61
Tocqueville Asset Management
New York
$2.46M +$1.8M +8,850 +196%
Canada Life
62
Canada Life
Manitoba, Canada
$2.46M +$221K +1,088 +9%
California Public Employees Retirement System
63
California Public Employees Retirement System
California
$2.39M
Wells Fargo
64
Wells Fargo
California
$2.37M +$1.05M +5,187 +67%
D.E. Shaw & Co
65
D.E. Shaw & Co
New York
$2.35M +$1.24M +6,081 +91%
OAM
66
Oxford Asset Management
United Kingdom
$2.29M -$4.38M -21,527 -63%
Manulife (Manufacturers Life Insurance)
67
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$2.28M +$382K +1,879 +18%
BG
68
Bellevue Group
Switzerland
$2.28M
OPPM
69
Opus Point Partners Management
New York
$2.26M +$105K +515 +4%
CS
70
Candriam SCA
Luxembourg
$2.15M -$339K -1,666 -12%
USAA
71
United Services Automobile Association
Texas
$2.14M
Comerica Bank
72
Comerica Bank
Texas
$2.1M +$333K +1,637 +18%
BA
73
BlackRock Advisors
Delaware
$2.02M +$1.3M +6,393 +140%
EU
74
Emory University
Georgia
$1.87M +$2.07M +10,171 New
RJA
75
Raymond James & Associates
Florida
$1.81M +$489K +2,404 +32%

NKTR Hedge Fund Activity: Q4 2016 in Review

199 of the 4,001 institutional investors tracked by Wall St. Rank reported a position in Nektar Therapeutics (NKTR) for Q4 2016, worth a combined $1.78B — down 22% from $2.28B a quarter earlier.

Buyers outnumbered sellers: 37 funds opened new NKTR positions and 28 closed out — a net gain of 9 holders — while 101 added to existing stakes and 34 trimmed.

The largest buyer was BlackRock Fund Advisors, adding an estimated $38.9M. The largest seller was RA Capital Management, exiting entirely with an estimated $63M sold.

  • 199 institutional investors held Nektar Therapeutics (NKTR) as of Q4 2016, up from 194 in Q3 2016.
  • Funds reported $1.78B of Nektar Therapeutics stock for Q4 2016, down 22% quarter-over-quarter.
  • 37 funds opened new Nektar Therapeutics positions in Q4 2016 and 28 closed out, a net change of +9 holders.
  • The largest Nektar Therapeutics buyer in Q4 2016 was BlackRock Fund Advisors, an estimated $38.9M added.
  • The largest Nektar Therapeutics seller in Q4 2016 was RA Capital Management, an estimated $63M sold.

Based on aggregated 13F filings for Q4 2016.